Tattevin P, Uhel F, Fily F. Observational studies of salvage treatment for persistent bacteremia: beware of survivor treatment selection bias. Clin Infect Dis. 2009;49:1960; author reply 1961. doi: 10.1086/648500. 174. Falagas ME, Manta KG, Ntziora F, Vardakas KZ. Linezolid for the treat- ment of patients with endocarditis: a systematic review of the published evidence. J Antimicrob Chemother. 2006;58:273 280. doi: 10.1093/jac/ dkl219. 175. Schwalm JD, El-Helou P, Lee CH. Clinical outcome with oral linezolid and rifampin following recurrent methicillin-resistant Staphylococcus aureus bacteremia despite prolonged vancomycin treatment. Can J Infect Dis. 2004;15:97 100. 176. Mu oz P, Rodr guez-Creix ms M, Moreno M, Mar n M, Ramallo V, Bouza E; GAME Study Group. Linezolid therapy for infec- tive endocarditis. Clin Microbiol Infect. 2007;13:211 215. doi: 10.1111/j.1469-0691.2006.01585.x. 177. Sander A, Beiderlinden M, Schmid EN, Peters J. Clinical experience with quinupristin-dalfopristin as rescue treatment of critically ill patients infected with methicillin-resistant staphylococci. Intensive Care Med. 2002;28:1157 1160. doi: 10.1007/s00134-002-1358-7. 178. Nace H, Lorber B. Successful treatment of methicillin-resistant Staphylococcus aureus endocarditis with telavancin. J Antimicrob Chemother. 2010;65:1315 1316. doi: 10.1093/jac/dkq113. 179. Ho TT, Cadena J, Childs LM, Gonzalez-Velez M, Lewis JS 2nd. Methicillin-resistant Staphylococcus aureus bacteraemia and endocar- ditis treated with ceftaroline salvage therapy. J Antimicrob Chemother. 2012;67:1267 1270. doi: 10.1093/jac/dks006. 180. Lin JC, Aung G, Thomas A, Jahng M, Johns S, Fierer J. The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients. J Infect Chemother. 2013;19:42 49. doi: 10.1007/ s10156-012-0449-9. 181. Casapao AM, Davis SL, Barr VO, Klinker KP, Goff DA, Barber KE, Kaye KS, Mynatt RP, Molloy LM, Pogue JM, Rybak MJ. Large retro- spective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. Antimicrob Agents Chemother. 2014;58:2541 2546. doi: 10.1128/AAC.02371-13. 182. 